BASHH best practice statement on the management of testosterone-associated vulvovaginitis

Joe Smith, Sophie Ross, Kate Nambiar, Kathleen Rafferty, Madeleine Crow, Ruth Bond, Rudy Graves, The Laurels GIC, Devon Partnerships Trust, Brighton and Hove Sexual Health and Contraception Service, University Hospitals Sussex NHS Foundation Trust, Gender Identity Clinic, North London NHS Foundation Trust, Welsh Gender Service, Cardiff and Vale University Health Board, Department of Sexual Health, Vale University Health Board, Wellington Clinic Sexual and Reproductive Health Service, Sexual Wellbeing Aotearoa, New Zealand, Locala Sexual Health Bradford, Leeds Gender Identity Service, Leeds York Partnership Foundation Trust, Sexual Health Research Midwife, Leeds Teaching Hospitals NHS Trust

International Journal of STD & AIDS: Clinical practice in sexual health

Published online on June 16, 2026

Abstract

International Journal of STD & AIDS, Volume 37, Issue 9, Page 984-994, August 2026.
BackgroundTestosterone-associated vulvovaginitis is an under-recognised cause of genital symptoms in transmasculine patients receiving testosterone as gender-affirming hormone therapy, with 5-years prevalence 64-78%. BASHH’s Gender and Sexual Minorities ...